Tim Smith

These data indicate that greater maternal dietary diversity during pregnancy may be linked with a diminished risk of atopic dermatitis during early childhood.

This study compared a recent risk prediction tool for invasive melanoma and its performance compared to existing prediction tools.

These data underscore the value of individualized cancer risk evaluations when selecting treatment strategies for psoriasis.

Preliminary topline results have been released from the ASCEND study on rocatinlimab in adults and adolescents with atopic dermatitis.

Investigators systematically reviewed NB-UVB treatment responses for psoriasis in patients with skin of color.

This announcement highlights delgocitinib cream availability for the treatment of US adults living with moderate-to-severe chronic hand eczema, or CHE.

In this observational analysis, investigators highlight the potential causal link identified between NHHR and psoriasis development.

Investigators explored the characteristics of pediatric-onset hidradenitis suppurativa, emphasizing the need for earlier detection to expedite diagnosis.

NB-UVB phototherapy was highlighted in this study, with positive findings suggesting the treatment is an effective oral cyclosporine alternative.

Investigators highlighted the cardiovascular safety of systemic treatments for psoriasis such as methotrexate and tumor necrosis factor inhibitors.

Amlitelimab met its primary and key secondary endpoints in the COAST 1 phase 3 study of adults and adolescents with atopic dermatitis.

This analysis highlights bimekizumab’s impact on psoriasis clearance compared to ustekinumab, secukinumab, and adalimumab.

This announcement regarding the new sNDA for roflumilast cream in pediatric patients with psoriasis follows positive findings from the MUSE study.

This study highlighted VTE risk factors in a cohort of patients with alopecia areata who were eligible for baricitinib treatment.

In this analysis, investigators looked at the importance of skin clearance and daily time trade off (dTTO) among adult patients living with chronic hand eczema (CHE).

This analysis looked at a Hispanic patient cohort, systematically linking specific trichoscopic patterns with clinical outcomes related to scalp psoriasis.

This Month in Review summary includes a list of some of the most notable stories in the dermatology field from August 2025.

This analysis highlights the global prevalence of HS and some of the most significant global variations in HS prevalence.

This analysis suggests that this AI model effectively classifies skin irritation in patch tests, allowing for quicker and more accurate dermatologic assessments.

Up to half of psoriasis patients report significant psychiatric symptoms, highlighting the importance of routine screening in practice.

These findings on teledermatology highlight its effectiveness as a potential solution for disparities in dermatology care within rural communities.

These data on roflumilast cream 0.3% highlight the medication’s efficacy and safety in pediatric patients aged 2 - 11 years.

This study compared the N-NAIL diagnostic tool to NAPSI, highlighting results among patients with nail psoriasis.

In this analysis, a variety of alternative therapies for hair loss, such as oils, stem cells, and laser treatments, were highlighted for their potential.

This review highlights phase 3 and long-term data on deucravacitinib therapy for patients with plaque psoriasis.

Oral supplementation with a novel dietary AGA-P supplement was shown to increase the clinical efficacy of pharmacological treatments for androgenic alopecia.

The investigators present pooled findings from the SUNSHINE and SUNRISE trials assessing secukinumab therapy for HS.

This study highlights a significant link between alopecia areata and autoimmune thyroid disease, assessing a large-scale and diverse population.